Cinnamon May Be Used to Halt the Progression of Parkinson’s disease

Neurological scientists at Rush University Medical Center have found that using cinnamon, a common food spice and flavoring material, can reverse the biomechanical, cellular and anatomical changes that occur in the brains of mice with Parkinson’s disease (PD). The results of the study were recently published in the June 20 issue of the Journal of Neuroimmune Pharmacology.

“Cinnamon has been used widely as a spice throughout the world for centuries,” said Kalipada Pahan, PhD, study lead researcher and the Floyd A. Davis professor of neurology at Rush. “This could potentially be one of the safest approaches to halt disease progression in Parkinson’s patients.”

“Cinnamon is metabolized in the liver to sodium benzoate, which is an FDA-approved drug used in the treatment for hepatic metabolic defects associated with hyperammonemia,” said Pahan. It is also widely used as a food preservative due to its microbiocidal effect.

Chinese cinnamon (Cinnamonum cassia) and original Ceylon cinnamon (Cinnamonum verum) are two major types of cinnamon that are available in the US.

“Although both types of cinnamon are metabolized into sodium benzoate, by mass spectrometric analysis, we have seen that Ceylon cinnamon is much more pure than Chinese cinnamon as the latter contains coumarin, a hepatotoxic molecule,” said Pahan.

“Understanding how the disease works is important to developing effective drugs that protect the brain and stop the progression of PD,” said Pahan. “It is known that some important proteins like Parkin and DJ-1 decrease in the brain of PD patients.”

The study found that after oral feeding, ground cinnamon is metabolized into sodium benzoate, which then enters into the brain, stops the loss of Parkin and DJ-1, protects neurons, normalizes neurotransmitter levels, and improves motor functions in mice with PD.

This research was supported by grants from National Institutes of Health.

“Now we need to translate this finding to the clinic and test ground cinnamon in patients with PD. If these results are replicated in PD patients, it would be a remarkable advance in the treatment of this devastating neurodegenerative disease,” said Dr. Pahan.

Parkinson’s disease is a slowly progressive disease that affects a small area of cells within the mid-brain known as the substantia nigra. Gradual degeneration of these cells causes a reduction in a vital chemical neurotransmitter, dopamine. The decrease in dopamine results in one or more of the classic signs of Parkinson’s disease that includes: resting tremor on one side of the body; generalized slowness of movement; stiffness of limbs; and gait or balance problems. The cause of the disease is unknown. Both environmental and genetic causes of the disease have been postulated.

Parkinson’s disease affects about 1.2 million patients in the United States and Canada. Although 15 percent of patients are diagnosed before age 50, it is generally considered a disease that targets older adults, affecting one of every 100 persons over the age of 60. This disease appears to be slightly more common in men than women.

Fight Control: Researchers link individual neurons to regulation of aggressive behavior in flies

Scientists have long pondered the roots of aggression—and ways to temper it. Now, new research is beginning to illuminate the cellular-level circuitry responsible for modulating aggression in fruit flies, with the hope of someday translating the findings to humans.

Researchers at Harvard Medical School have identified two pairs of dopamine-producing neurons, also called dopaminergic neurons, and traced their aggression-modulating action to a common structure in the fly brain called the central complex, suggesting that important components of aggression-related behaviors may be processed there.

“This is the first research to identify single dopaminergic neurons that modulate a complex behavior—aggression—in fruit flies,” said Edward Kravitz, George Packer Berry Professor of Neurobiology at HMS and lead author of the study.

“We don’t know how complex this modulatory circuit is, but we now have a key element of it. If we eliminate or increase the function of that dopaminergic neuron, it affects the circuit of the brain responsible for controlling aggression,” Kravitz said.

The findings were published last week in PNAS.

Flies are an ideal animal model for neurological research because genetic methods allow scientists to manipulate neurons and simultaneously observe the resulting behaviors. Many fundamental nervous system mechanisms in flies are similar to those in humans. In fact, both flies and humans share the same neurohormones.

Dopamine is one such neurohormone, and across species it affects a range of behaviors, from learning and memory to motivation and movement. In humans, neurohormones are associated with conditions such as Parkinson’s disease and psychiatric disorders.

Dopaminergic neurons are found in small numbers in particular parts of nervous systems. In humans, there are about 200,000 to 400,000 of these neurons; in fruit flies there are about 100. While their numbers are few, these neurons influence a vast array of behaviors.

Kravitz, along with Olga Alekseyenko, a postdoctoral fellow in the Kravitz lab and first author on the paper, set out to discover how these few dopaminergic neurons can influence such a wide range of behaviors.

To do this, study co-first author, Yick-Bun Chan, HMS research associate in neurobiology, genetically engineered 200 lines of fruit flies. He then used them to target select dopaminergic neurons that could be activated or silenced while the flies engaged in various behaviors.

The team detected two pairs of dopaminergic neurons that affected aggressive behavior in the flies. Interestingly, aggression was increased in the flies either by augmenting the function of these cells or by deactivating them.

In fruit flies, males fight for territory and form stable hierarchical relationships. Using previous observations and analysis of more than 20,000 interactions in fly fights, the team established quantitative measures of aggressive behavior, such as lunging, that allowed them to compare aggression levels in different fly attacks.

“When we turned off the pairs of dopaminergic neurons, the flies fought with more lunging; when we turned them on, they also fought at higher intensity levels. Apparently normal levels of aggression require a precise amount of dopamine released at a specific time and place in the nervous system. These results suggest that these neurons ordinarily hold aggression in check,” said Alekseyenko.

Also significant was the finding that while the two sets of dopaminergic neurons modulated aggression, they did not influence other behaviors.

The first pair of neurons are found in the PPM3 cluster of neurons in the fly brain and the second are within the T1 cluster. Both pairs innervate different parts of the central complex, an important structure in the fly brain.

“We already knew that dopamine receptors are present in the central complex, but we didn’t know which dopamine neurons connected to the receptors or what behaviors those neurons affected,” said Alekseyenko.

“Now we know that two pairs of aggression-mediating dopaminergic neurons terminate in different regions of the central complex, and we know that those regions have different types of dopamine receptors. Our study shows that aggression is one of the behaviors coordinated in these regions of the brain, but we still don’t fully understand the process,” he said.

In a third group of flies, a neuron pair that projected into a different part of the brain was identified. These neurons affected locomotion and sleep, but did not influence aggression.

Kravitz said the next phase of the research will be to use genetic tools to allow his team to identify the subsequent steps in the brain circuitry—which neurons are pre- and post-synaptic to the T1 and PPM3 neurons and how that affects neuronal network function.

The goal will be to establish fundamental principles for how dopaminergic neurons work in the fruit fly system, with the hope that the research will one day translate to how these neurons work in higher species. This may ultimately aid in the development of new dopamine-targeted medications for humans.

“We can now relate these two pairs of neurons specifically to one behavior, and that is aggression,” Kravitz said. “That means we have one piece of the puzzle.”

Shedding Light on Early Parkinson’s Disease Pathology

In a mouse model of early Parkinson’s disease (PD), animals displayed movement deficits, loss of tyrosine-hydroxylase (TH)-positive fibers in the striatum, and astro-gliosis and micro-gliosis in the substantia nigra (SN), without the loss of nigral dopaminergic neurons. These findings, which may cast light on the molecular processes involved in the initial stages of PD, are available in the current issue of Restorative Neurology and Neuroscience.

“The most intriguing finding of our study was the lack of a significant decrease of TH levels in the SN of the low-dose MPTP-treated mice, suggesting that this treatment does not induce a direct loss of nigral dopaminergic neurons,” says Joost Verhaagen PhD, lead investigator of the study. “These findings appear to support the ‘dying back’ hypothesis of PD, which proposes that the TH-positive terminal loss in the striatum is the first neurodegenerative event in PD, which later induces neuronal degeneration in the SN.” Dr. Verhaagen is Head of the Workgroup on Neuroregeneration at the Netherlands Institute for Neuroscience and Professor at the Free University in Amsterdam.

The neurotoxin MPTP (1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine) was used to induce the degenerative changes. Chronic 5 week administration of 25 mg/kg MPTP combined with probenecid (250 mg/kg), which inhibits MPTP clearance and promotes its crossing of the blood-brain barrier, is known to cause dopaminergic neuron degeneration in the SN and decrease striatal dopaminergic nerve terminals. In the current study, 7 mice were treated with 25 mg/kg MPTP plus probenecid, 6 mice received a lower dose of MPTP (15 mg/kg) plus probenecid, and 8 control mice received saline plus probenecid. A grid test, known to be sensitive to striatal dopaminergic input, was used to detect motor deficits.

Immunohistochemical analysis using TH fluorescence revealed that only the higher dose of MPTP produced significant dopaminergic neuronal cell loss in the SN (65% fluorescence loss, p<0.001). The 15 mg/kg dose produced an 18% decline in fluorescence which was not significantly different than control.

Both dose levels significantly reduced TH immunoreactivity of the striatum. The authors believe that the motor deficits seen at both MPTP dose levels relate to the striatal dopamine depletion.

The study is also the first to report that low-dose MPTP produces astrogliosis and microgliosis in the SN and formation of α-synuclein positive inclusions. “The data suggests that gliosis in the substantia nigra plays a prominent initiating role in the introduction of dopaminergic deficits after MPTP treatment, and may be sufficient to significantly reduce TH levels in the striatum,” says Dr. Korecka, first author and principal investigator of the study and a post-doctoral fellow at the Netherlands Institute for Neuroscience in Amsterdam.

“We are the first to report that this early PD model provides an interesting window of opportunity to study the mechanisms that underlie the early neurodegenerative events that initiate the cellular death of dopaminergic neurons,” write the authors. They suggest that the model can be used to develop potential treatment strategies to counteract early PD cellular changes.

(Image: iStock)

Research Institute Study Shows How Brain Cells Shape Temperature Preferences

While the wooly musk ox may like it cold, fruit flies definitely do not. They like it hot, or at least warm. In fact, their preferred optimum temperature is very similar to that of humans—76 degrees F.

Scientists have known that a type of brain cell circuit helps regulate a variety of innate and learned behavior in animals, including their temperature preferences. What has been a mystery is whether or not this behavior stems from a specific set of neurons (brain cells) or overlapping sets.

Now, a new study from The Scripps Research Institute (TSRI) shows that a complex set of overlapping neuronal circuits work in concert to drive temperature preferences in the fruit fly Drosophila by affecting a single target, a heavy bundle of neurons within the fly brain known as the mushroom body. These nerve bundles, which get their name from their bulbous shape, play critical roles in learning and memory.

The study, published in the January 30, 2013 edition of the Journal of Neuroscience, shows that dopaminergic circuits—brain cells that synthesize dopamine, a common neurotransmitter—within the mushroom body do not encode a single signal, but rather perform a more complex computation of environmental conditions.

“We found that dopamine neurons process multiple inputs to generate multiple outputs—the same set of nerves process sensory information and reward-avoidance learning,” said TSRI Assistant Professor Seth Tomchik. “This discovery helps lay the groundwork to better understand how information is processed in the brain. A similar set of neurons is involved in behavior preferences in humans—from basic rewards to more complex learning and memory.”

Using imaging techniques that allow scientists to visualize neuron activity in real time, the study illuminated the response of dopaminergic neurons to changes in temperature. The behavioral roles were then examined by silencing various subsets of these neurons. Flies were tested using a temperature gradient plate; the flies moved from one place to another to express their temperature preferences.

As it turns out, genetic silencing of dopaminergic neurons innervating the mushroom body substantially reduces cold avoidance behavior. “If you give the fly a choice, it will pick San Diego weather every time,” Tomchik said, “but if you shut down those nerves, they suddenly don’t mind being in Minnesota.”

The study also showed dopaminergic neurons respond to cooling with sudden a burst of activity at the onset of a drop in temperature, before settling down to a lower steady-state level. This initial burst of dopamine could function to increase neuronal plasticity—the ability to adapt—during periods of environmental change when the organism needs to acquire new associative memories or update previous associations with temperature changes.

(Image: ALAMY)

Genetic manipulation of urate alters neurodegeneration in mouse model of Parkinson’s disease

A study by Massachusetts General Hospital researchers adds further support to the possibility that increasing levels of the antioxidant urate may protect against Parkinson’s disease. In their report published in PNAS Early Edition, the investigators report that mice with a genetic mutation increasing urate levels were protected against the kind of neurodegeneration that underlies Parkinson’s disease, while the damage was worse in animals with abnormally low urate.

"These results strengthen the rationale for investigating whether elevating urate in people with Parkinson’s can slow progression of the disease," says Xiqun Chen, MD, PhD, of the MassGeneral Institute for Neurodegenerative Diseases (MGH-MIND) and lead author of the PNAS report. “Our study is the first demonstration in an animal model that genetic elevation of urate can protect dopamine neurons from degeneration and that lowering urate can conversely exacerbate neurodegeneration.”

Characterized by tremors, rigidity, difficulty walking and other symptoms, Parkinson’s disease is caused by destruction of brain cells that produce the neurotransmitter dopamine. Healthy people whose urate levels are at the high end of the normal range have been found to be at reduced risk of developing Parkinson’s disease. Studies led by Michael Schwarzschild, MD, PhD, director of Molecular Neurobiology Laboratory at MGH-MIND, showed that, among Parkinson’s patients, symptoms appear to progress more slowly in those with higher urate levels. These observations led Schwarzschild and his colleagues to develop the SURE-PD (Safety of URate Elevation in Parkinson’s Disease) clinical trial, conducted at sites across the country through the support of the Michael J. Fox Foundation. Expected in early 2013, the results of SURE-PD will determine whether a medication that elevates urate levels should be tested further for its ability to slow the progression of disability in Parkinson’s disease.

Autologous mesenchymal stem cell–derived dopaminergic neurons function in parkinsonian macaques

A cell-based therapy for the replacement of dopaminergic neurons has been a long-term goal in Parkinson’s disease research. Here, we show that autologous engraftment of A9 dopaminergic neuron-like cells induced from mesenchymal stem cells (MSCs) leads to long-term survival of the cells and restoration of motor function in hemiparkinsonian macaques. Differentiated MSCs expressed markers of A9 dopaminergic neurons and released dopamine after depolarization in vitro. The differentiated autologous cells were engrafted in the affected portion of the striatum. Animals that received transplants showed modest and gradual improvements in motor behaviors. Positron emission tomography (PET) using [¹¹C]-CFT, a ligand for the dopamine transporter (DAT), revealed a dramatic increase in DAT expression, with a subsequent exponential decline over a period of 7 months. Kinetic analysis of the PET findings revealed that DAT expression remained above baseline levels for over 7 months. Immunohistochemical evaluations at 9 months consistently demonstrated the existence of cells positive for DAT and other A9 dopaminergic neuron markers in the engrafted striatum. These data suggest that transplantation of differentiated autologous MSCs may represent a safe and effective cell therapy for Parkinson’s disease.